Accessibility Menu
Profound Medical Stock Quote

Profound Medical (NASDAQ: PROF)

$6.35
(-1.9%)
-0.12
Price as of November 13, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$6.35
Daily Change
(-1.9%) $0.12
Day's Range
$6.06 - $6.50
Previous Close
$6.35
Open
$6.30
Beta
1.01
Volume
84,962
Average Volume
130,720
Market Cap
190.8M
Market Cap / Employee
$6.35M
52wk Range
$3.76 - $8.75
Revenue
-
Gross Margin
0.74%
Dividend Yield
N/A
EPS
-$1.45
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Profound Medical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PROF-22.28%-65.88%-19.34%-38%
S&P+12.57%+87.93%+13.44%+218%

Profound Medical Company Info

Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.21M-1.0%
Gross Profit$1.62M13.9%
Gross Margin73.18%9.5%
Market Cap$177.31M-13.5%
Market Cap / Employee$1.25M0.0%
Employees1428.4%
Net Income-$15.70M-126.8%
EBITDA-$13.67M-79.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$35.20M3.3%
Accounts Receivable$4.18M-33.4%
Inventory8.424.1%

Liabilities

Q2 2025YOY Change
Long Term Debt$4.53M5.5%
Short Term Debt$0.28M-87.8%

Ratios

Q2 2025YOY Change
Return On Assets-81.99%-29.4%
Return On Invested Capital-45.71%5.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$14.15M-130.3%
Operating Free Cash Flow-$14.15M-130.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book4.975.962.893.49-21.89%
Price to Sales22.9518.1214.4515.07-46.67%
Price to Tangible Book Value5.016.032.913.51-22.29%
Enterprise Value to EBITDA-19.86-17.70-11.80-10.83-54.68%
Return on Equity-91.7%-60.7%-66.4%-104.2%55.10%
Total Debt$6.15M$5.12M$4.88M$4.81M-26.85%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.